Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further detailing and validating its approach to combat food-induced immune disorders with its SOMIT (Specific OroMucosal ImmunoTherapy) platform technology. The first study, published with collaborators from Madrid in Frontiers in Immunology, validates Allero’s SOMIT approach of addressing the oral mucosa […]
continue readingAllero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the […]
continue reading